High Content Screening Market

The global high-content screening (HCS) market is consolidated in nature with the top five players commanding a major share of the market. GE Healthcare (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Becton, Dickinson and Company (U.S.) lead the global market. Some of the other leading players in this market include BioTek Instruments Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Tecan Group Ltd. (Switzerland), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).

Danaher Corporation holds a leading position in the market. The company designs, manufactures, and markets professional, medical, industrial, and commercial products & services. Danaher Corporation primarily focuses on product launches as its key business strategy. For example, in February 2017, Molecular Devices, LLC (U.S.), a subsidiary of Danaher Corporation, launched the SpectraMax iD3 Multi-Mode Microplate Reader. This added another platform to the company’s portfolio to expand its reach in the HCS market. In April 2016, Molecular Devices, LLC (U.S.) launched the ImageXpress Micro 4 High-content Imaging System. This further strengthened the company’s HCS product portfolio.

Thermo Fisher Scientific Inc. is one of the top players in the market. The company operates in more than 180 countries across North America, Europe, Asia, and Latin America. It offers HCS instruments and software among other products. The company focuses on product launches as its key business strategy. In May 2016, the company launched the Invitrogen Evos FL Auto 2 Imaging System to provide rapid capture and analysis of higher-quality images in live-cell imaging experiments. In addition, in January 2016, Thermo Fisher Scientific launched the Cell Insight CX7 high-content analysis platform. This strengthened the company’s hold in the HCS market.

Becton, Dickinson and Company (BD) is one of the major players in the market. The company has a strong presence in the HCS market due to its extensive product portfolio, ranging from instruments to accessories in flow cytometry. It operates globally through a network of offices across North America, Europe, Asia-Pacific, Eastern Europe, the Middle East, and Africa. To maintain its position in the market, the company has been focusing on technological advancements in flow cytometry. In the last three years, the company has launched several products, such as the BD FACSMelody System, BD FACSymphony, BD FACSPresto system, BD FACSCelesta system, and BD FACSVia flow cytometer.

The key strategies adopted by major players in the global high-content screening market are agreements, partnerships & collaborations, acquisitions, product launches, and geographic expansions. In this competitive market, global players aim to maintain their market position through continuous investments in R&D with a focus on developing innovative solutions or enhancing their existing solutions.

Related Reports:

High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: [email protected]